Mentioned in ?
References in periodicals archive ?
If the intravenous combination of amiodarone and beta-blockers proves inefficacious, the addition of lidocaine is a reasonable option.1,2 For what concerns the prevention of ES, interesting results have been yielded by some drugs such as azimilide, a class III antiarrhythmic.
Schwartz et al., "Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification," Circulation, vol.
M2 EQUITYBITES-April 20, 2011-Forest Laboratories and Blue Ash Therapeutics signs asset purchase agreement for azimilide for ventricular arrhythmias(C)2011 M2 COMMUNICATIONS
The other class III antiarrhythmics in trials like ambasilide and azimilide are non selective blockers as they block both [I.sub.Kr] and [I.sub.Ks] respectively (32,53).
(25.) Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, et al; AzimiLide post Infarct survival Evaluation (ALIVE) Investigators.
* Azimilide. This agent acts by blocking both rapid and slow potassium channels in myocardium, and is chemically distinct from other class III antiarrhythmic drugs like sotalol, amiodarone, and dofetilide.
(8) Class 1A and class III antiarrhythmic agents that may be involved in these events include amiodarone, azimilide, bepridil, bretylium, disopyramide, dofetilide, D-sotalol, flecainide, ibutilide, procainamide, propafenone, quinidine, and tedisamil.
Azimilide is the one believed closest to the marketplace; marketing approval in the United States and Europe may be only a few months away, according to Dr.
Leading researchers who study heart arrhythmia --or irregular heartbeat -- have reported the results from a pivotal clinical trial on the investigational anti-arrhythmic drug, azimilide, in development by Procter & Gamble Pharmaceuticals.
And Azimilide, an antiarrhythmia drug, will begin clinical trials this summer.
* Azimilide. This agent blocks both rapid and slow potassium channels in the heart and is one of the drugs under FDA review.
Marketing approval was recently granted for dofetilide, a "pure" class III antiarrhythmic agent and is anticipated this year for azimilide, a similar agent.